OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Applied Clinical Trials
(St. Louis; March 10, 2015)– Biomedical Systems, a premier global provider of centralized diagnostic services, launches its second generation clinical outcome assessment software offering three easy-to-use platforms to collect patient data. This new electronic patient recorded outcome (ePRO) technology improves patient and investigator user experience, improves patient compliance and expedites study setup by simplifying site tasks and reducing errors.
Biomedical Systems’ electronic clinical outcome assessment (eCOA) technology is used for clinical trials in more than 40 countries for multiple therapeutic areas including respiratory, gastrointestinal, dermatology, oncology and women’s health. Biomedical Systems is the only company providing eCOA technology along with cardiac safety, pulmonary function and imaging centralized diagnostic services.
“The eCOA market is growing fast, and launching this technology enhances our ability to offer centralized diagnostic services,” said Tim Barrett, chief executive officer at Biomedical Systems. “In 40 years, Biomedical Systems has built a premier global presence based on centralized diagnostic services and logistics excellence. Our eCOA solutions will extend that prompt, reliable global service we’re known for to provide more reliable data while collecting data for primary and secondary endpoints.”
Biomedical Systems’ eCOA technology offers the flexibility, reliability and robustness of the Android operating system. QR code technology is used to reduce investigators’ burden, improve security and, more importantly, ease the data capture process. With this platform, Biomedical Systems focused on patients’ ease of use by providing new features that improve compliance and worldwide reliable data transmission using the latest telecommunication technologies. In addition, Biomedical Systems relies on a strong and proactive project management team that is key to successful eCOA trials.